| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element™ Everolimus-Eluting Platinum...
-
Oct 10, 2012
First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System REPRISE II Study Results Expected to Support CE Mark and Other...
-
Oct 8, 2012Pending Addition of Next Generation Mapping and Navigation System Would Expand Company Portfolio into Complex Electrophysiology Procedures
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions...
-
Aug 28, 2012S-ICD System is the World's First and Only Commercially Available Completely Subcutaneous Implantable Defibrillator
The U.S. Food and Drug Administration has granted Boston Scientific Corporation (NYSE: BSX) regulatory approval for its S-ICD® System, the world's first and only commercially available...
-
Aug 28, 2012
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its PRECISION™ PLUS SPINAL CORD STIMULATOR (SCS) System in patients with the system and are in need for...
-
Aug 27, 2012
PRECISION™ PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval for Peripheral Nerve Stimulation Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its...
-
Aug 26, 2012Newly Revised European Society of Cardiology Guidelines Include LAA Closure Devices
European regulators have approved an expanded indication for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients...
-
Aug 24, 2012RELIANCE® 4-FRONT™ Lead Designed to Streamline Surgical Procedure for Treatment of Heart Failure and Sudden Cardiac Arrest
Boston Scientific Corporation (NYSE: BSX) has received regulatory approval to market the RELIANCE® 4-FRONT™ lead, its next generation implantable defibrillation lead now available in Europe and...
-
Jul 27, 2012First European Implants of INGENIO™ MRI Pacemaker with New Image Ready™ Technology Performed This Week
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for use of its INGENIO™ and ADVANTIO™ pacemakers in patients in need of a magnetic resonance imaging (MRI) scan. Now...
-
Jul 2, 2012S-ICD® System selected as most innovative in the field of Electrophysiology and Cardiac Techniques
Attendees of Cardiostim 2012, a global medical conference held recently in Nice, France, have selected the S-ICD® System recently acquired by Boston Scientific Corporation (NYSE: BSX) as the most...